SOURCE: MMIT Analytics, as of 6/11/19
Wednesday, June 12, 2019
Insys Therapeutics this week filed for...
...Chapter 11 bankruptcy, just a
few days after paying $225 million to settle a federal investigation that found
the company bribed doctors to prescribe its leading drug Subsys, a fentanyl
spray typically only used in cancer patients who are already taking other
opioids. Subsys currently holds preferred status for 16% of covered lives, and
is not covered for 25% of lives.
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment